|
|
Upfront Briefing
BIO 2026 kicks off in San Diego today, and the BD desks didn't wait for the coffee — Insilico banked an up-to-$2.5B AI pact with SK Biopharm (on all of $18M upfront), while MoonLake flexed one-year HS durability into its Investor Day. Backloaded promises and a genuine data print, side by side.
The other shoe is policy: Washington opened a Section 301 front on German drug prices, with Korea reportedly next in the queue — which lands awkwardly close to the day's marquee Korean dealmaker.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,500.6 |
+1.1% |
+9.4% |
| Nasdaq 100 |
30,406.2 |
+2.5% |
+20.6% |
| Russell 2000 |
2,979.8 |
+2.1% |
+18.8% |
| Healthcare (XLV) |
149.4 |
(0.9%) |
(3.9%) |
| Biotech (XBI) |
140.7 |
+1.0% |
+15.8% |
| Nasdaq Biotech (NBI) |
6,020.5 |
0.0% |
+5.5% |
| Clinical Trials (BBC) |
45.5 |
+1.4% |
+20.8% |
|
- Biotech rode the high-beta bid into the holiday break: XBI +1.0% as small-caps led on easing yields, while large-cap pharma defensives lagged (XLV (0.9%)). The split was positioning, not a single-name catalyst — no pivotal print or FDA action moved the group Thursday.
- The tape was a rebound from Wednesday's hawkish-Fed selloff. Warsh's first FOMC held at 3.50–3.75%, but the dot plot flipped toward a 2026 hike (9 of 18 officials), and stocks clawed it back Thursday as yields eased — Russell 2000 +2.1% out front, Nasdaq 100 +2.5%, with Intel +10.6% on a Trump-flagged Apple chip tie-up dragging semis higher.
- Market data: U.S. cash close Thursday, 18 June 2026 (U.S. markets closed Friday for Juneteenth).
The Big 3
|
1
|
Insilico, SK Biopharm strike up-to-$2.5B AI neuro deal
|
- Insilico Medicine and SK Biopharmaceuticals struck an AI-powered drug discovery collaboration worth up to $2.5B in neuroimmune disorders, with the structure described as heavily backloaded.
- Why it matters: The $2.5B headline is almost all bio-dollars — Insilico takes only up to $18M in upfront and near-term cash, with the rest stacked behind development, regulatory and commercial milestones plus single-digit royalties. SK Biopharm gets a capital-light push into neuroimmune CNS beyond its cenobamate epilepsy base and steers late-stage development; Insilico books its largest APAC deal by headline value and another proof point that big partners will pay — mostly on success — for AI-native discovery, the same template as its ~$2.75B Lilly pact. The catch: it's discovery-stage, the economics are contingent, and both names trade in Asia (3696.HK, 326030.KS), not on U.S. tape.
- Source: Fierce Biotech
- More: PR
|
|
2
|
MoonLake posts week 52 Phase 3 VELA data for sonelokimab
|
- Sonelokimab held up at one year: ~67% of patients hit HiSCR75 across the Phase 3 VELA-1/VELA-2 trials (68.3% and 66.0%), 33.1% reached HiSCR100 and 26.0% hit inflammatory remission (IHS4-100), with no new safety signals. MoonLake (Nasdaq: MLTX) traded up ~10% and confirmed an Investor Day for today, June 22.
- Why it matters: Week 16 earned sonelokimab the BLA conversation; week 52 is the durability proof, and ~67% HiSCR75 at one year reads ahead of where entrenched IL-17 biologics land at the same timepoint — the case for premium HS positioning. The +10% move says the buy-side was carrying durability risk into the print. From here the debate shifts to launch timing and peak-sales math, which is exactly what today's Investor Day has to frame. Risk: these aren't head-to-head comparisons, and a crowded HS field (bimekizumab, secukinumab, the TNF base) still sets the reimbursement bar.
- Source: BioSpace
- More: Company release; Investing.com
|
| 3 | US launches probe into German drug pricing |
-
The U.S. government launched an investigation into German drug pricing, with the summary citing Section 301 of the Trade Act of 1974 and Germany’s plan to pay less for drugs.
- Why it matters: This is the MFN pricing fight crossing the Atlantic — USTR is using Section 301, the same tool aimed at China in 2018, to argue Germany underpays for innovation, with tariffs on German pharma exports (APIs and finished dose) on the table if it advances. The near-term P&L hit is small; the signal isn't. Comment submissions open June 25 and a hearing is set for September, so it runs as an overhang on ex-U.S. pricing assumptions rather than a one-day event. Watch the read-through: USTR has already named Korea as next in line — which lands on the same names anchoring today's SK Biopharm headline.
- Source: Endpoints
- More: BioSpace
|
Everything Else that broke
- Moderna's mRNA flu shot won unanimous FDA advisory support ahead of an expected Aug. 5 decision. — BioSpace
- uniQure posted first-cohort Phase I/IIa AMT-260 epilepsy data with no serious adverse events observed to date. — PR
- Japan approved Sanofi's subcutaneous Sarclisa for multiple myeloma, adding a lifecycle-management lever in anti-CD38. — PR
- FDA warned Zoll Medical over quality-control and device-reporting violations, raising remediation and reputational risk. — Fierce Biotech
- Critics raised broader concerns around FDA's National Priority Voucher program and who gets chosen. — BioSpace
- BioCentury flagged continuing signs of political involvement in FDA decision-making and dispute access. — BioCentury
- CureGene dosed the first participant in the U.S. pivotal trial for antiplatelet Evategrel (CG-0255). — PR
- Kither completed Phase 1 testing of inhaled peptide KIT2014 in healthy participants. — PR
- EMA's CVMP issued a negative opinion on Scovella (velagliflozin) marketing authorisation. — EMA
- New Sanofi CEO Belén Garijo replaced R&D chief Houman Ashrafian with Roche and Xaira alum Paulo Fontoura, effective Sept. 1 — a pipeline reset after a run of Phase 3 setbacks. — Fierce Biotech
- Pfizer's CFO Dave Denton exits Aug. 15 for a consumer-goods role, with finance SVP Cecile Guegan stepping in on an interim basis while an external search runs; shares slipped 3.5%. — Fierce Pharma
- Denali sold an FDA priority review voucher for $195M, a non-dilutive boost for its neurodegenerative pipeline. — BioSpace
- BioSpace argued cell and gene therapy still faces structural pressure from regulators, manufacturers and payers. — BioSpace
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Insilico and SK Biopharm inked an up-to-$2.5B AI drug-discovery collaboration in neuroimmune disorders (see The Big 3). — Fierce Biotech
- Antengene licensed ATG-106 to K2 Therapeutics and added an option on an undisclosed bispecific TCE. — PR
- BioArctic and Lilly paired a Lilly compound with BrainTransporter technology in a CNS research collaboration. — PR
VC / Private Financings
- Memento Medicines closed a $93M Series A to advance MMT-205, a Tie2-activating / VEGF-inhibiting bispecific for nAMD and DME — co-led by Forbion, RA Capital and Avego BioScience Capital, with Sanofi Ventures and Samsara BioCapital joining. — BioSpace
IPOs / Follow-Ons
- Kardigan's $400M IPO and aftermarket gains kept the biotech new-issue window in focus. — BioCentury
|
Backloaded bio-dollars, a one-year HS flex, and Washington picking a pharma fight with Berlin — see you tomorrow. — BioBucks Team
|
|
|
